Tactile Systems Technology, Inc. has demonstrated remarkable financial resilience and strategic foresight in its second-quarter performance for 2026. The company achieved a notable 9% surge in total revenue, driven by robust growth in its lymphedema sector. Despite facing temporary challenges within its airway clearance segment due to inventory rebalancing, Tactile Systems Technology has not only maintained its adjusted EBITDA projections but has also laid clear pathways for future expansion and innovation. Their steadfast commitment to improving patient access, broadening therapeutic offerings, and elevating patient experiences underscores a robust business model poised for sustained, profitable growth.
Tactile Systems Technology's Q2 2026 Performance and Future Outlook
On Monday, August 10, 2026, Tactile Systems Technology (TCMD) convened its second-quarter earnings call, providing a detailed overview of its impressive financial achievements and strategic advancements. Key executives, including CEO Sheri Dodd and CFO Elaine Birkemeyer, alongside Investor Relations representative Sam Bentzinger, elaborated on the company's progress and future trajectory.
The company reported a substantial 9% year-over-year increase in total revenue, reaching an impressive $85.7 million. This growth was predominantly propelled by the flourishing lymphedema product line, which alone generated $73.6 million, marking a 12% rise from the previous year. This segment's success is attributed to healthy referral trends and enhanced productivity across sales territories.
However, the airway clearance revenue, primarily from AffloVest, experienced a temporary 7% decline to $12.1 million. This dip was a direct consequence of inventory management adjustments by major distributors following the launch of Tactile Systems' next-generation AffloVest system. Despite this short-term setback, the trailing 12-month revenue for AffloVest still shows a robust 32% increase, indicating strong underlying market demand.
Profitability saw significant expansion, with a gross margin of 76.3%, an increase of 180 basis points year-over-year, driven by reduced manufacturing costs and a favorable product mix. Adjusted EBITDA soared by 49% to $11.4 million, reflecting operational efficiencies and stringent expense control. Net income more than doubled, reaching $7.8 million, up from $3.2 million in the prior year, resulting in diluted EPS of $0.34.
Tactile Systems Technology has updated its full-year 2026 revenue guidance to a range of $360 million to $366 million, reflecting continued strength in lymphedema and a more conservative outlook for airway clearance due to inventory dynamics. The company maintains its adjusted EBITDA guidance of $49 million to $51 million, underscoring confidence in its strategic initiatives and operational discipline.
Strategic priorities remain focused on enhancing patient access, broadening treatment options, and maximizing lifetime patient value. The company's efforts include integrating the LymphaTech software for improved lymphedema diagnosis and monitoring, and securing exclusive U.S. distribution rights for the MyoSleeve device, targeting veterans and active-duty service members through the Department of Defense. Furthermore, the publication of 6-month clinical data for Flexitouch in head and neck lymphedema patients in a prestigious medical journal reinforces the product's efficacy and safety, aiming to improve commercial payor coverage.
The leadership team, including CEO Sheri Dodd and CFO Elaine Birkemeyer, expressed confidence in the company's ability to navigate market dynamics, citing successful preparation for new Medicare prior authorization requirements and ongoing improvements in operational efficiency. The company ended the quarter with a healthy cash balance of $69.9 million, providing ample flexibility for future investments and shareholder returns.
The latest financial disclosures from Tactile Systems Technology paint a picture of a company actively evolving and adapting to market shifts while maintaining a firm grip on its core growth drivers. The strategic acquisition and integration of LymphaTech and the distribution agreement for MyoSleeve are particularly noteworthy, signaling a concerted effort to diversify revenue streams and address unmet patient needs. These moves, coupled with robust clinical evidence supporting existing products, suggest a future where patient outcomes are not only improved but also accessed more broadly. The emphasis on leveraging existing infrastructure for new product launches, as highlighted by CFO Elaine Birkemeyer, is a smart play that minimizes overhead while maximizing market penetration. It's clear that Tactile Systems Technology is not just selling medical devices; it's building a comprehensive ecosystem around patient care, driven by innovation and strategic partnerships. This holistic approach should resonate well with investors looking for sustainable growth in the healthcare sector.
